LBI-HTA - Publications - Search - Horizon Scanning in Oncology 38th Prioritisation – 1st quarter 2019

Grössmann, N. and Wolf, S. and Rothschedl, E. (2019): Horizon Scanning in Oncology 38th Prioritisation – 1st quarter 2019. HSO: 38th Prioritisation.

[img]PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
127Kb
Abstract

For the 38th prioritisation (January 2019), ten drugs were filtered out of 502 identified and were sent to prioritisation. Of these, three drugs were ranked as 'highly relevant' by the expert panel, seven as 'relevant' and none as 'not relevant'. For 'highly relevant' drugs, further information including, for example, abstracts of phase III studies and licensing status is contained in this document

Item Type:DSD: Horizon Scanning in Oncology
Subjects:WB Practice of medicine > WB 300-962 Therapeutics
QZ Pathology > QZ 200-380 Neoplasms.Cysts
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Language:English
Series Name:HSO: 38th Prioritisation
Deposited on:16 Jan 2019 18:35
Last Modified:16 Jan 2019 18:35

Repository Staff Only: item control page